Managing chronic hepatitis C in the difficult-to-treat patient

Liver International

Volumn 27, Issue 10, 2007, Pages 1297-1310

  Kemmer, Nyingi ^a   Neff, Guy W ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Consensus interferon; HepatitisC; Non responders; Pegylated interferon; Relapsers; Retreatment; Ribavirin; Sustained virological response

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CONSENSUS INTERFERON; CYCLOSPORIN; INTERFERON; LIVER ENZYME; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AGE DISTRIBUTION; ANEMIA; ANOREXIA; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEARING LOSS; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INJECTION SITE IRRITATION; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NOSE CONGESTION; OBESITY; PNEUMONIA; PREDICTION; PRURITUS; PSORIASIS; RACE DIFFERENCE; RELAPSE; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEIZURE; SIDE EFFECT; SUPERINFECTION; THROMBOCYTOPENIA; THYROIDITIS; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION;

EID: 36348949135     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01613.x     Document Type: Review

References (131)

1. Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 60. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2005.
2. Management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; June 10-12; 19: 1-46.
3. Armstrong GL, Wasley A, Simard EP, Mcquillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
4. Lo Re V III, Kostman JR. Management of chronic hepatitis C. Postgrad Med J 2005; 81: 376-82.
5. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
6. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
7. Centers for Disease Control and Prevention. Disease burden from viral hepatitis A, B, and C in the United States. Updated: 2004. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/ disease_burden2004.pdf. Accessed on 29 October 2007.
8. Shiffman ML. Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. Curr Gastroenterol Rep 2006; 8: 46-52.
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. Manns MP, Mchutchison JG, the International Hepatitis Interventional Therapy Group, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
11. Mchutchison JG, Gordon SC, for the Hepatitis Interventional Therapy Group, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
12. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332: 1457-62.
13. Shiffman ML. Management of patients with chronic hepatitis C virus infection and previous nonresponse. Rev Gastroenterol Disord 2004; 4 (Suppl. 1): S22-30.
14. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment. Clin Infect Dis 2005; 40 (Suppl. 5): S263-9.
15. Loguercio C, Di PM, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000; 35: 296-301.
16. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-9.
17. Franceschi S, Montella M, Polesel J, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15: 683-9.
18. Pawlotsky JM. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol 2006; 299: 261-84.
19. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-9.
20. Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842-8.
21. Pawlotsky JM. Hepatitis C virus genetic variability: Pathogenic and clinical implications. Clin Liver Dis 2003; 7: 45-66.
22. Namba K, Naka K, Dansako H, et al. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype. Biochem Biophys Res Commun 2004; 323: 299-309.
23. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-35.
24. Boulestin A, Kamar N, Sandres-Saune K, et al. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Med Virol 2006; 78: 365-71.
25. Carlsson T, Reichard O, Norkrans G, et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005; 12: 473-80.
26. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002; 97: 1813-20.
27. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
28. Jessner W, Stauber R, Hackl F, et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 2003; 10: 37-42.
29. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004; 4 (Suppl. 1): S31-8.
30. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
31. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
32. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.
33. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-84.
34. Layden-Almer JE, Layden TJ. Viral kinetics in hepatitis C virus: Special patient populations. Semin Liver Dis 2003; 23 (Suppl. 1): 29-33.
35. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71.
36. Reddy KR, Hoofnagle JH, for the Consensus Interferon Study Group, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 787-93.
37. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7.
38. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-50.
39. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7: 196-202.
40. Fontana RJ, Kleiner DE, Bilonick R, et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006; 44: 925-35.
41. Koyama R, Arase Y, Ikeda K, et al. Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2006; 49: 121-6.
42. Terranova R, Luca S. Preliminary results of beta-interferon treatment in the elderly. Control Clin Trials 1996; 17: 123-9.
43. Terranova R, Luca S. Treatment of chronic hepatitis C with lymphoblastoid interferon alpha in elderly patients. Eur Rev Med Pharmacol Sci 1997; 1: 47-52.
44. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
45. Hu K-Q, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: A retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40: 147-54.
46. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 1177-86.
47. Eguchi Y, Mizuta T, Yasutake T, et al. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12: 556-60.
48. Jianwu Y, Shuchen L, Gui-Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 2006; 26: 166-72.
49. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001; 21: 266-71.
50. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-35.
51. Hickman IJ, Clouston AD, MacDonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.
52. Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16: 23-9.
53. O'Leary JG, Chung RT. Management of hepatitis C virus coinfection in HIV-infected persons. AIDS Read 2006; 16: 313-20.
54. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
55. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
56. Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/ HIV coinfection. J Infect Dis 2003; 188: 1498-507.
57. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023-8.
58. Soriano V, Nunez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9: 505-9.
59. Sulkowski MS. Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. J Hepatol 2006; 44 (Suppl. 1): S49-55.
60. Kadam JS, Talal AH. Changing treatment paradigms: Hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS 2007; 21: 154-68.
61. Roche B, Samuel D. Aspects of hepatitis C virus infection relating to liver transplantation. Eur J Gastroenterol Hepatol 2006; 18: 313-20.
62. de Vera ME, Smallwood GA, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678-86.
63. Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001; 7: 870-6.
64. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transplant 2001; 7: 863-9.
65. Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 1253-8.
66. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000-6.
67. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623-9.
68. Giostra E, Kullak-Ublick GA, Keller W, et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004; 17: 169-76.
69. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.
70. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247-52.
71. Boyanova Y, Pissaia A, Conti F, Soubrane O, Calmus Y. Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment. Presse Med 2006; 35 (Part 1): 233-6.
72. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005; 41: 289-98.
73. Bizollon T, Adham M, Pradat P, et al. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005; 79: 325-9.
74. Bizollon T, Pradat P, Mabrut JY, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007; 7: 448-53.
75. Fabrizi F, Bunnapradist S, Lunghi G, Aucella F, Martin P. Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence. Minerva Urol Nefrol 2004; 56: 249-57.
76. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: A multicenter study. J Med Virol 2000; 61: 44-51.
77. Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37: 1004-10.
78. Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: A nationwide prospective study. J Infect Dis 2000; 182: 1291-9.
79. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-18.
80. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669-74.
81. Pereira BJ, Natov SN, The New England Organ Bank Hepatitis C Study Group, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53: 1374-81.
82. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-34.
83. di Belgiojoso GB, Ferrario F, Landriani N. Virus-related glomerular diseases: Histological and clinical aspects. J Nephrol 2002; 15: 469-79.
84. Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996; 7: 2469-75.
85. Cruzado JM, Carrera M, Torras J, Grinyo JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-8.
86. Gallay BJ, Alpers CE, Davis CL, Schultz MF, Johnson RJ. Glomerulonephritis in renal allografts associated with hepatitis C infection: A possible relationship with transplant glomerulopathy in two cases. Am J Kidney Dis 1995; 26: 662-7.
87. Hammoud H, Haem J, Laurent B, et al. Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 1996; 11 (Suppl. 4): 54-5.
88. Roth D, Cirocco R, Zucker K, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59: 1676-82.
89. Weiner SM, Thiel J, Berg T, et al. Impact of in vivo complement activation and cryoglobulins on graft outcome of HCV-infected renal allograft recipients. Clin Transplant 2004; 18: 7-13.
90. Rossi P, Bertani T, Baio P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-41.
91. Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: Implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82: 853-6.
92. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81.
93. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.
94. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol 2005; 63: 232-5.
95. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 991-3.
96. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575-80.
97. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437-43.
98. Kalia H, Lopez PM, Martin P. Treatment of HCV in patients with renal failure. Arch Med Res 2007; 38: 628-33.
99. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-5.
100. Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30: 110-4.
101. Calanca LN, Fehr T, Jochum W, et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol 2007; 39: 54-8.
102. Harihara Y, Kurooka Y, Yanagisawa T, Kuzuhara K, Otsubo O, Kumada H. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26: 2075.
103. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-70.
104. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343-53.
105. Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104-6.
106. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625-8.
107. Wong T, Lee SS. Hepatitis C: A review for primary care physicians. CMAJ 2006; 174: 649-59.
108. Sjogren MH, Sjogren R, Holtzmuller K, et al. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005; 50: 727-32.
109. Gross J, Johnson S, the RENEW investigators, et al. Double-dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: Final results of "RENEW" [abstract]. Hepatology 2005; 42 (Suppl. 1): 219A-20A. Abstract 60.
110. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. J Hepatol 2006; 44: 291-301.
111. Böcher WO, Schuchmann M, Link R, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 2006; 26: 319-25.
112. Miglioresi L, Bacosi M, Russo F, et al. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res 2003; 27: 253-9.
113. Bacon B, Regev A, Ghalib R, et al. Use of daily interferon alfacon-1 (Infergen®, CIFN) plus ribavirin (RBV) in patients infected with hepatitis C (HCV) who are nonresponders to previous pegylated interferon plus RBV therapy: 24-week data from the DIRECT trial [abstract]. Hepatology 2006; 44 (Suppl. 1): 698A. Abstract LB18.
114. Lawitz EJ, Bala NS, Alamo Study Group, et al. Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy [abstract]. Gastroenterology 2003; 124 (Suppl. 1): A-783. Abstract 1293.
115. Poynard T, Schiff EG, Terg R, et al. Sustained virologic response (SVR) in the EPIC3 trial: Week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD) [abstract]. J Hepatol 2005; 42 (Suppl. 2): 40-1. Abstract 96.
116. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
117. Teuber G, Kallinowski B, Niederau C, et al. Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin [abstract]. Gastroenterology 2003; 124 (Suppl. 1). A-699 Abstract 1216.
118. Alric L, Duffaut M, Selves J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001; 35: 272-8.
119. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-72.
120. National Institutes of Health Clinical Trials web site, Updated: 2006. Available at: http://www.clinicaltrials.gov/ct/action/GetStudy. Accessed on 29 October 2007.
121. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472-92.
122. Pawlotsky J-M, Gish RG. Future therapies for hepatitis C. Antivir Ther 2006; 11: 397-408.
123. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-33.
124. Hayashida K, Daiba A, Sakai A, et al. Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2005; 3: 1253-9.
125. Herrmann E, Zeuzem S. The kinetics of hepatitis C virus. Eur J Gastroenterol Hepatol 2006; 18: 339-42.
126. Terrault NA, Pawlotsky JM, Mchutchison J, et al. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat 2005; 12: 465-72.
127. Carlsson T, Weiland O, Reichard O. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. Scand J Gastroenterol 2002; 37: 1228-34.
128. Glue P, Fang JW, the Hepatitis C Intervention Therapy Group, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556-67.
129. Jo YW, Youn YS, Lee SH, et al. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int J Pharm 2006; 309: 87-93.
130. Ouzan D, Khiri H, Penaranda G, Joly H, Halfon P. Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naive genotype 1 patients. Comp Hepatol 2005; 4: 9.
131. Lee WM, Reddy KR, the Consensus Interferon Study Group, et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998; 28: 1411-5.